Nuvectis Pharma, Inc.
Close on Oct 19, 2026
- Market cap
- $444.64M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
About Nuvectis Pharma
Pharmaceutical Preparations, SIC 2834
Nuvectis Pharma is a clinical-stage biopharmaceutical company that develops precision therapeutics for serious cancer conditions. Its lead product candidate is NXP900, an oral small-molecule targeted inhibitor of SRC and YES1 kinases currently evaluated in clinical trials for advanced solid tumors. The firm previously evaluated another oncology candidate, NXP800, before halting its clinical development. As an early-stage development business with no commercialized treatments, the company does not operate commercial sales segments or serve end consumers; its drug candidates are tested in cancer patients enrolled in clinical trials.
The company maintains its executive office in Fort Lee, New Jersey. Nuvectis owns no manufacturing plants, instead relying on single-source third parties to manufacture drug substances and finished products for clinical testing. The company holds exclusive global commercial rights to its primary drug candidate under a license from Scotland, with intellectual property protections spanning the United States, the European Union, China, Japan, and Canada.
Summary of the business section of Nuvectis Pharma's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Nuvectis Pharma, Inc.
- Founded
- 2020
- Headquarters
- Fort Lee, NJ
- Address
- 1 Bridge Plaza, Suite 275 07024
- Phone
- (360) 837-7232
- Website
- nuvectis.com
- Employees
- 13, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers International Limited, Tel-Aviv,Israel
Stock & identifiers
- Ticker
- NVCT
- Exchange
- Nasdaq
- IPO date
- Feb 7, 2022
- Shares outstanding
- 33M, Jul 31, 2026
- Public float
- $100.00M, Dec 31, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1875558
- CUSIP
- 67080T108
- ISIN
- US67080T1088
- EIN
- 86-2405608
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Ron Bentsur | Chairman & CEO, Director | 3,688,424 |
| Michael J. Carson | Vice President, Finance | 230,118 |
| Shay Shemesh | Chief Dev. & Ops. Officer | 1,793,068 |
| Enrique Poradosu | Chief Science & Business Off | 1,806,319 |
| Juan Sanchez | Director | 113,795 |
| Kenneth Hoberman | Director | 168,140 |
| James F. Oliviero III | Director | 122,828 |
| Matthew L. Kaplan | Director | 159,760 |
Employees
Headcount reported in annual reports
“As of February 6, 2026, we had 13 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Feb 7, 2022 | IPO | Initial public offering priced (424B4 prospectus) |
| Feb 3, 2022 | Listing | Registration of securities on an exchange (Form 8-A) |